[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Naples\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":99},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100616414","mirabegron-in-patients-with-age-related-macular-degeneration-100616414",false,"NCT07305298","Mirabegron in Patients With Age-Related Macular Degeneration","Mirabegron in Patients With Age-Related Macular Degeneration Treated for Overactive Bladder: A Study Protocol for a Non-Randomized Prospective Controlled Trial","Inclusion Criteria:\n\n* Age subjects 50 and 80 years-old\n* Ability to express informed consent\n* Early or moderate dry AMD according to ARDS classification\n* Overreactive bladder\n* Visual acuity greater than BCVA 65 EDTRS letters.\n\nExclusion Criteria:\n\n* • Any medical condition which contraindicates the use of beta-agonists\n\n  * Uncontrolled hypertension\n  * Tachycardia or atrial fibrillation\n  * Any allergies to the beta-agonists\n  * Renal or hepatic failure\n  * Long QT or concomitant treatment with drugs that cause lengthening of the QT interval\n  * Any sign of ocular inflammation\n  * xudative AMD\n  * Any ongoing medical or surgical treatment for AMD (including intravitreal injections, oral supplementation of lutein, zeaxanthin and or high dietary intake of antioxidants)\n  * Any other ophthalmic diseases such glaucoma, acute or chronic uveitis, advanced cataract, or any opacities of the ocular media that do not permit high-quality imaging examinations.\n  * Pregnancy\n  * Any condition or disease that in the opinion of the investigators may put the subject at significant risk or may interfere significantly with the subject's participation in the study (i. e. malignancy, uncontrolled or cardiovascular diseases)","ALL","50 Years","80 Years",{"count":20,"type":21},312,"ESTIMATED","OBSERVATIONAL","The goal of this clinical trial is to learn if Mirabegron works to treat dry AMD in patients, aged between 50 and 80 years-old, with early or moderate dry AMD and overactive bladder.\n\nThe main question it aims to answer is:\n\n• Is there any change in outer retina morphology in patients treated?\n\nResearchers will compare the safety and efficacy of mirabegron versus conventional approach (Solifenacin) to treat dry AMD in patients with dry AMD and overactive bladder.\n\nParticipants will:\n\n* Take Mirabegron or Solifenacin every day for 12 months\n* Visit the clinic once every 6 months for checkups and tests",[25,26],"Dry AMD","Overactive Bladder","NOT_YET_RECRUITING","2026-02-04",{"date":30,"type":31},"2026-02-06","ACTUAL",{"date":33,"type":21},"2026-04-01",{"date":35,"type":21},"2026-12-01",{"name":37,"class":38},"University of Naples","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":39},"100564475","robotic-versus-laparoscopic-sleeve-gastrectomy-100564475","NCT06629662","Robotic Versus Laparoscopic Sleeve Gastrectomy","Robotic Versus Laparoscopic Sleeve Gastrectomy: Prospective Randomized Study.","SLEEVEROBOP","Inclusion Criteria:\n\n* According to IFSO (International Federation for the Surgery of Obesity)\u002FASMBS (American Society for Metabolic and Bariatric Surgery) 2023 guidelines\n\nExclusion Criteria:\n\n* Previous bariatric or abdominal surgery","18 Years","65 Years",{"count":51,"type":21},50,"INTERVENTIONAL",[54],"NA","Sleeve gastrectomy is the most commonly performed bariatric procedures. Robotic surgery seems to add more precision to the surgical interventions. However, robotic bariatric procedures appear to be burdened by longer operative time.\n\nAim of the investigators is to prospectively and randomly submit patients suffering from obesity to robotic or laparoscopic surgery in order to compare outcomes.",[57],"Robotic Surgery",[59,60,61],"Robotic surgery","Sleeve Gastrectomy","Bariatric surgery","RECRUITING","2025-03-29",{"date":65,"type":31},"2025-04-03",{"date":67,"type":31},"2024-10-01",{"date":69,"type":21},"2025-11-01",{"name":37,"class":38},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":52,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100530294","phase-3-preventing-celiac-disease-by-weaning-with-mediterranean-diet-100530294","NCT06184906","Preventing Celiac Disease by Weaning With Mediterranean Diet","PEMED","Inclusion Criteria:\n\n* \\- Healthy newborns with a birth weight greater than 2000 grams.\n* Residence in Municipality 8, Piscinola-Scampia.\n\nExclusion Criteria:\n\n* \\- Newborns suffering from severe prematurity.\n* Newborns with congenital malformations.\n* Newborns afflicted by severe diseases.","1 Month","10 Months",{"count":81,"type":21},3200,[83],"PHASE3","Background: The introduction of solid foods in alignment with the Mediterranean Diet (MD) post-exclusive milk feeding has been demonstrated to cultivate a lasting affinity for healthy eating during infancy and childhood. Despite this, access to healthy diets remains a challenge for numerous children, particularly in underserved areas. The clinical trial under discussion is set in Scampia, a municipality in Naples, Italy, known for its dense population and socio-economic challenges. This trial, utilizing the Family Pediatrician (FP) system, aims to promote MD nutrition among children in Scampia to potentially prevent or reduce chronic childhood diseases.\n\nStudy Design: In this pragmatic trial, FPs are utilized as the unit for randomization to administer the intervention. The intervention group will be introduced to an intensified MD-based diet from weaning, incorporating adult-type MD foods, while the control group will follow standard regional dietary guidelines. Dietary adherence and health outcomes are to be periodically monitored, and genetic and microbiome analyses will be conducted using collected saliva and stool samples. Incorporating a Bayesian group sequential design, this trial is structured to conduct interim analyses for efficacy, aligning with local healthcare systems for optimal resource allocation.\n\nConclusion: The study is poised to be methodologically innovative and socially impactful, utilizing existing healthcare frameworks to enhance childhood nutrition in challenging environments. Outcomes from this trial are expected to provide valuable insights into the effects of MD-based nutrition on child health and potentially serve as a model for promoting healthier diets in urban suburbs globally.",[86],"Weaning Failure",[88,89,90],"Infant Weaning","Mediterranean Diet","Celiac Disease","2024-05-07",{"date":93,"type":31},"2024-05-08",{"date":95,"type":21},"2024-06-15",{"date":97,"type":21},"2030-12-31",{"name":37,"class":38},""]